Inhibition of IL-33/ST2 may reduce NF-κB mediated transcriptional upregulation of PD-L1 in tumour and stromal cells, thereby enhancing response to PD-1/PD-L1 blockade [129]. Here, NFKB1 is linked to neoplasm.